An observational study in Chronic Pain Syndrome, sponsored by Hospital Ambroise Paré Paris. Recruiting at 2 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Hospital Ambroise Paré Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 135 studies in Chronic Pain with a site in France — 35 open to participants now, 39 under way, 2 of them phase 3. Chronic Pain · France.
Among the 135 studies in Chronic Pain with a site in France, this one is the 36th largest by planned enrollment of the 68 observational ones that give a count, is one of 10 that started in 2022, is one of 68 observational ones, reaches primary completion later than 3 of the 38 other live ones, and was the 112th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →35 of the 135 studies in Chronic Pain with a site in France are open now. Recruiting first, the newest first:
Nantes University Hospital · Sites in France
Ages 18+
Institut Rafael · Sites in France
Ages 18+
Hospital Ambroise Paré Paris · Sites in France
Ages 18–80
Centre Medical ISM (Integrative Systemic Medicine) · Sites in France
Ages 18+
Medtronic · Sites in France, United States, Belgium and 1 more country
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
135 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 13 · Phase 4 3
First in 2003; this study’s year is marked. 10 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 120 across 755 observational studies indexed under Chronic Pain.
Median enrollment 78 across the 67 interventional studies, 160 across the 68 observational. Of the 84 that completed or were terminated, 11 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 135 have an industry lead sponsor. The 10 most frequent:
Hospital Ambroise Paré Paris is the lead sponsor of 23 studies on the registry; 6 are open to participants now.
Hospital Ambroise Paré Paris has 4 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
14 of the studies in Chronic Pain with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06964243Institut pour la Pratique et l'Innovation en PSYchologie appliquée (Institut Pi-Psy)Protocol Assessment of Motor Cortex rTMS for Treating Neuropathic Pain | 2026-12-19 |
| NCT07877376Nadine ATTALImpact of Cognitive Impairment on Chronic Pain in Breast Cancer | 2027-01 |
| NCT06811077Fondation Hôpital Saint-JosephEvaluation of Individual Health Coaching Sessions Provided by a Patient Expert As Part of Therapeutic Education for Patients Registered At the Chronic Pain Consultation | 2027-01-15 |
| NCT07280338University Hospital, BrestEmotional Intelligence and Chronic Orofacial Pain | 2027-02-09 |
| NCT06841276NovesiaImpact of QoLibri Medical Device on the Consequences of Chronic Pain: a Randomized Controlled Trial | 2027-03 |
Add all 14 to your calendar (.ics) → With an account.
Among the 135 studies in Chronic Pain with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study will be to assess the proportion of fibromyalgia patients with diffuse small-fiber neuropathy (i.e. in the upper and lower limbs) and compare this proportion to patients with other chronic pains (nociplastic, nociceptive) and with healthy controls. Our analysis will be based on the demonstration of structural abnormalities of small nerve fibers by means of skin biopsy, but also of functional abnormalities using four validated tests commonly used in this field: quantitative sensory testing (QST), laser evoked potential recordings, Sudoscan and confocal corneal microscopy. It will thus be possible to verify whether or not patients with small fiber neuropathy have a particular clinical profile in terms of pain, physical activity, comorbidities or pain impact.
Small fiber neuropathy has been observed in a large proportion of fibromyalgia patients. However, the pathophysiological role of these neurological abnormalities in determining the pain and other symptoms of fibromyalgia, and the specificity of these abnormalities, are not well understood.
The primary objective of this study will be to assess the proportion of fibromyalgia patients with diffuse small-fiber neuropathy (i.e. in the upper and lower limbs) and compare this proportion to patients with other chronic pains (nociplastic, nociceptive) and with healthy controls. Our analysis will be based on the demonstration of structural abnormalities of small nerve fibers by means of skin biopsy, but also of functional abnormalities using four validated tests commonly used in this field: quantitative sensory testing (QST), laser evoked potential recordings, Sudoscan and confocal corneal microscopy. It will thus be possible to verify whether or not patients with small fiber neuropathy have a particular clinical profile in terms of pain, physical activity, comorbidities or pain impact.
Patients with fibromyalgia, other chronic pains (nociplastic or nociceptive) and healthy subjects
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with fibromyalgia based on ACR criteria
Diagnostic Test: Skin punch biopsy to demonstrate small fiber neuropathy
Patients with chronic pain other than fibromyalgia and neuropathic pain, eg nociplastic pains or nociceptive pains
Diagnostic Test: Skin punch biopsy to demonstrate small fiber neuropathy
Healthy subjects paired for gender and age
Diagnostic Test: Skin punch biopsy to demonstrate small fiber neuropathy
Skin punch biopsy to assess intrapidermal nerve fiber density
Also known as: Other diagnostic tests will include laser evoked potentiels, quantitative sensory testing, sudoscan, and confocal corneal microscopu
Prevalence of small fiber neuropathy or pathology as assessed with skin punch biopsy in patients with fibromyalgia as compared to patients with other chronic pains and healthy subjects
intraepidermal nerve fiber density
Time frame: Baseline and at 6 months
Correlation between intraepidermal nerve fiber density and pain or other patient reported outcome measures (quality of life, distress, disability...)
Correlation statistics (Spearman Rho)
Time frame: Baseline and at 6 months
Investigate the potential specificity of the results obtained by comparing them with pain patients without fibromyalgia or nerve damage (patients with any nociceptive or nociplastic pain without fibromyalgia) matched for age and gender
Direct group comparisons
Time frame: Baseline and at 6 months
Monitor the evolution of abnormalities obtained over time (6 months) and correlate them with the evolution of pain and associated symptoms.
Comparison of intraepidermal nerve fiber density and other diagnostic measures between baseline and 6 months
Time frame: 6 months
Determine the sensitivity and diagnostic value of corneal confocal microscopy and laser evoked potentials as compared with skin punch biopsy for exploring nociceptive fibers
Sensitivity and specificy of these tests compared to skin punch biopsy
Time frame: Baseline and at 6 months
Determine the diagnostic value of the sudoscan and quantified sensory tests compared with other tests for exploring nociceptive fibers in these patients
Sensitivity and specificy of sudoscan and quantitative sensory testing compared to skin punch biopsy
Time frame: Baseline and at 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2022 (actual). Primary completion is estimated for Dec 2025, 47 months after the start.
Of 337 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 56. This study's planned 47 months is above that.
Counting every sponsor, half of 363 studies reached it within 24 months; a quarter within 12 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Ambroise Paré Paris